Replies to post #114888 on Biotech Values

[DewDiligence]

1Q11 Angiomax sales were $112M, +10% YoY but -7% QoQ:

http://finance.yahoo.com/news/The-Medicines-Company-Reports-iw-3914193770.html?x=0&.v=1

Due to premium pricing, Angiomax remains almost entirely a US drug; 1Q11 ex-US sales were just $7M.